Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1
Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. NSCLC, in particular, has a high mortality rate attributed to late-...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1557193/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850123733650374656 |
|---|---|
| author | Yohan Seo Yohan Seo Sion Lee Raju Das Sung Baek Jeong Chul Soon Park Minuk Kim Deok Kyu Yoon Armin Sultana Kantu Das Jae-Eon Lee Yong Hyun Jeon Phan Thi Thanh Huong Nguyen Xuan Nhiem Joohan Woo Joohan Woo |
| author_facet | Yohan Seo Yohan Seo Sion Lee Raju Das Sung Baek Jeong Chul Soon Park Minuk Kim Deok Kyu Yoon Armin Sultana Kantu Das Jae-Eon Lee Yong Hyun Jeon Phan Thi Thanh Huong Nguyen Xuan Nhiem Joohan Woo Joohan Woo |
| author_sort | Yohan Seo |
| collection | DOAJ |
| description | Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. NSCLC, in particular, has a high mortality rate attributed to late-stage diagnosis and therapeutic resistance. Anoctamin 1 (ANO1), a calcium-activated chloride channel, has been implicated in cancer progression and is an emerging therapeutic target. In this study, we identified vitexicarpin, a flavonoid isolated from Vitex trifolia, as a novel ANO1 inhibitor with anticancer potential. Vitexicarpin inhibited ANO1 channel function, reduced ANO1 protein levels, decreased cancer cell viability, and induced apoptosis in CRC and NSCLC cell lines. Importantly, vitexicarpin exhibited minimal hepatotoxicity and negligible hERG channel inhibition, supporting its safety profile. Collectively, our findings suggest that vitexicarpin is a promising candidate for the treatment of CRC and NSCLC through selective inhibition of ANO1. |
| format | Article |
| id | doaj-art-078f7f2831ec446cbbb940683e836268 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-078f7f2831ec446cbbb940683e8362682025-08-20T02:34:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-05-011610.3389/fphar.2025.15571931557193Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1Yohan Seo0Yohan Seo1Sion Lee2Raju Das3Sung Baek Jeong4Chul Soon Park5Minuk Kim6Deok Kyu Yoon7Armin Sultana8Kantu Das9Jae-Eon Lee10Yong Hyun Jeon11Phan Thi Thanh Huong12Nguyen Xuan Nhiem13Joohan Woo14Joohan Woo15Department of Bio-nanomaterials, Bio Campus of Korea Polytechnics, Nonsan, Republic of KoreaNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of KoreaNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of KoreaDepartment of Physiology, Dongguk University College of Medicine, Gyeongju, Republic of KoreaNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of KoreaDepartment of Bio-nanomaterials, Bio Campus of Korea Polytechnics, Nonsan, Republic of KoreaDepartment of Medical Device Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDI hub), Daegu, Republic of KoreaDepartment of Medical Device Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDI hub), Daegu, Republic of KoreaDepartment of Physiology, Dongguk University College of Medicine, Gyeongju, Republic of KoreaDepartment of Computer Science, Southern University Bangladesh, Chittagong, BangladeshPreclincial Research Center (PRC), Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu, Republic of KoreaPreclincial Research Center (PRC), Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu, Republic of KoreaInstitute of Marine and Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi, VietnamInstitute of Marine and Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi, VietnamDepartment of Physiology, Dongguk University College of Medicine, Gyeongju, Republic of KoreaChannelopathy Research Center (CRC), Dongguk University College of Medicine, Goyang, Gyeonggi-do, Republic of KoreaColorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. NSCLC, in particular, has a high mortality rate attributed to late-stage diagnosis and therapeutic resistance. Anoctamin 1 (ANO1), a calcium-activated chloride channel, has been implicated in cancer progression and is an emerging therapeutic target. In this study, we identified vitexicarpin, a flavonoid isolated from Vitex trifolia, as a novel ANO1 inhibitor with anticancer potential. Vitexicarpin inhibited ANO1 channel function, reduced ANO1 protein levels, decreased cancer cell viability, and induced apoptosis in CRC and NSCLC cell lines. Importantly, vitexicarpin exhibited minimal hepatotoxicity and negligible hERG channel inhibition, supporting its safety profile. Collectively, our findings suggest that vitexicarpin is a promising candidate for the treatment of CRC and NSCLC through selective inhibition of ANO1.https://www.frontiersin.org/articles/10.3389/fphar.2025.1557193/fullANO1vitexicarpincolorectal cancernon-small cell lung cancerapoptosis |
| spellingShingle | Yohan Seo Yohan Seo Sion Lee Raju Das Sung Baek Jeong Chul Soon Park Minuk Kim Deok Kyu Yoon Armin Sultana Kantu Das Jae-Eon Lee Yong Hyun Jeon Phan Thi Thanh Huong Nguyen Xuan Nhiem Joohan Woo Joohan Woo Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1 Frontiers in Pharmacology ANO1 vitexicarpin colorectal cancer non-small cell lung cancer apoptosis |
| title | Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1 |
| title_full | Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1 |
| title_fullStr | Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1 |
| title_full_unstemmed | Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1 |
| title_short | Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1 |
| title_sort | vitexicarpin suppresses colorectal and non small cell lung cancer via selective inhibition of anoctamin 1 |
| topic | ANO1 vitexicarpin colorectal cancer non-small cell lung cancer apoptosis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1557193/full |
| work_keys_str_mv | AT yohanseo vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT yohanseo vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT sionlee vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT rajudas vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT sungbaekjeong vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT chulsoonpark vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT minukkim vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT deokkyuyoon vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT arminsultana vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT kantudas vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT jaeeonlee vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT yonghyunjeon vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT phanthithanhhuong vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT nguyenxuannhiem vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT joohanwoo vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 AT joohanwoo vitexicarpinsuppressescolorectalandnonsmallcelllungcancerviaselectiveinhibitionofanoctamin1 |